Tomoyuki Hashimoto
Shimane University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tomoyuki Hashimoto.
Journal of Gastroenterology and Hepatology | 2003
Kyoichi Adachi; Tomoyuki Hashimoto; Naoharu Hamamoto; Kazuya Hirakawa; Masatoshi Niigaki; Tatsuya Miyake; Hiroyuki Taniura; Masahiro Ono; Takekazu Kaji; Hiroshi Suetsugu; Junko Yagi; Yoshinori Komazawa; Takafumi Mihara; Tomoko Katsube; Hirofumi Fujishiro; Toshihiro Shizuku; Shuzo Hattori; Shun Yamamoto; Yoshikazu Kinoshita
Background and Aim: Rabeprazole has a faster onset of antisecretory activity than omeprazole and lansoprazole. The aim of the present study was to clarify whether there is any difference in the speed of symptom relief in patients with reflux esophagitis following the administration of these three proton pump inhibitors (PPI).
Alimentary Pharmacology & Therapeutics | 2000
Shunji Ishihara; Takekazu Kaji; Akira Kawamura; Mohammad Ak Rumi; Hiroshi Sato; Toshihiko Okuyama; Kyoichi Adachi; Ryo Fukuda; M. Watanabe; Tomoyuki Hashimoto; Kazuya Hirakawa; Yumi Matsushima; Tsutomu Chiba; Yoshikazu Kinoshita
Helicobacter pylori eradication therapy has been commonly performed for patients with peptic ulcer. An inexpensive, reliable, non‐invasive test would be useful for evaluation of the effectiveness of eradication therapy.
Journal of Gastroenterology and Hepatology | 2006
Hirofumi Fujishiro; Kyoichi Adachi; Tomonori Imaoka; Tomoyuki Hashimoto; Naruaki Kohge; Nobuyuki Moriyama; Hiroshi Suetsugu; Kousaku Kawashima; Yoshinori Komazawa; Norihisa Ishimura; Shunji Ishihara; Yuji Amano; Yoshikazu Kinoshita
Background and Aim: Endoscopic retrograde cholangiopancreatography (ERCP) is a useful diagnostic and therapeutic procedure; however, ERCP occasionally causes post‐ERCP pancreatitis. The administration of gabexate mesilate has been reported to be effective for the prevention for post‐ERCP pancreatitis when given during and after the procedure. The aim of the present study was to investigate the preventive effect of the novel protease inhibitor ulinastatin on post‐ERCP pancreatitis.
Alimentary Pharmacology & Therapeutics | 2005
Yoshikazu Kinoshita; Tomoyuki Hashimoto; Akira Kawamura; M. Yuki; Kazutoshi Amano; Hiroshi Sato; Kyoichi Adachi; Shuichi Sato; Naoki Oshima; T. Takashima; N. Kitajima; K. Abe; H. Suetsugu
Background : An effective therapeutic strategy for functional dyspepsia (FD) has not been well‐established.
Digestive Endoscopy | 1997
Tomoyuki Hashimoto; Kyoichi Adachi
Abstract: We used the laser Doppler method to study the difference in gastric mucosal blood flow changes between peptic ulcer (65 cases) and artificial ulcer caused by endoscopic mucosal resection (35 cases) during their respective healing processes. At each endoscopic ulcer stage, blood flow at the ulcer margin and that in the surrounding mucosa were measured. In the artificial ulcer, which heals easily, blood flow at the ulcer margin was still high at the scarring stage as compared with that in the corresponding area of a peptic ulcer, which is prone to relapse. Moreover, the blood flow ratio (blood flow at the ulcer margin/blood flow in the surrounding mucosa) at the S1 stage in artificial ulcers was significantly higher than that in peptic ulcers (p<0.05). These results suggest that blood flow in the SI stage is an important aspect of ulcer healing and relapse.
Alimentary Pharmacology & Therapeutics | 2002
Tomoyuki Hashimoto; Kyoichi Adachi; Norihisa Ishimura; Kazuya Hirakawa; Tomoko Katsube; A. Kurotani; Shuzo Hattori; Yoshikazu Kinoshita
Glucagon inhibits digestive motility and is used for endoscopic premedication; however, its effect on cardiopulmonary function during endoscopy has not yet been fully investigated.
Alimentary Pharmacology & Therapeutics | 2001
Kyoichi Adachi; Shunji Ishihara; Tomoyuki Hashimoto; Kazuya Hirakawa; Norihisa Ishimura; M. Niigaki; Takekazu Kaji; Akira Kawamura; Hiroshi Sato; Hirofumi Fujishiro; S. Hattori; Makoto Watanabe; Yoshikazu Kinoshita
: The cytoprotective agent, ecabet sodium, inhibits urease activity and growth of Helicobacter pylori.
Journal of Gastroenterology and Hepatology | 2006
Nobuo Ashizawa; Tomoyuki Hashimoto; Tatsuya Miyake; Toshihiro Shizuku; Tomonori Imaoka; Yoshikazu Kinoshita
Background: Differentiation between functional dyspepsia and early chronic pancreatitis is difficult because these diseases do not produce specific abnormalities in laboratory testing. The aim of this study was to examine the potential efficacy of camostat mesilate, a protease inhibitor, against functional dyspepsia and to characterize patients with favorable responses.
Alimentary Pharmacology & Therapeutics | 2001
Shunji Ishihara; Toshihiko Okuyama; Norihisa Ishimura; M. Ono; Tomoyuki Hashimoto; Hideaki Kazumori; Takekazu Kaji; Hiroshi Sato; Hirofumi Fujishiro; Kyoichi Adachi; Ryo Fukuda; Yoshikazu Kinoshita
There is controversy about the effect of acid‐suppressive therapy on Helicobacter pylori density and the severity of histological gastritis in the corpus.
Journal of Gastroenterology and Hepatology | 2005
Naoharu Hamamoto; Tomoyuki Hashimoto; Kyoichi Adachi; Kazuya Hirakawa; Shunji Ishihara; Harue Inoue; Hiroyuki Taniura; Masatoshi Niigaki; Shuichi Sato; Yoshinori Kushiyama; Hiroshi Suetsugu; Tatsuya Miyake; Yoshikazu Kinoshita
Background: The therapeutic effect of combined administration of prokinetics and histamine H2 receptor antagonists (H2RA) in gastroesophageal reflux disease is reported to be superior to that of monotherapy with H2RA alone. In addition to its acid‐suppressing effect, the H2RA nizatidine also has a prokinetic action by suppressing acetylcholine esterase. The present multicenter, randomized controlled study was performed to investigate whether nizatidine is superior to famotidine, which does not suppress acetylcholine esterase activity, in maintenance therapy for erosive esophagitis. In addition, the question as to whether the grade of erosive esophagitis affects the non‐recurrence rate during the maintenance therapy with H2RA was also investigated.